ALC

THE LEGEND CONTINUES… New York City's Iconic Fashion Retailer, Century 21 Re-Opens Tomorrow at its Flagship Location

Retrieved on: 
Monday, May 15, 2023
DNA, Human, Music, Cortlandt Street, Food, ALC, Code, Woman, Language, Department store, LoveShackFancy, Kappa, New Yorker, Fendi, Givenchy, Love, Goodman, Century, Century 21, Family, Nightclub, Theory, List of financial districts, Sovere

Tomorrow - May 16, 2023 -  The beloved retailer and purveyor of off-price luxury fashion is re-opening the doors of its flagship location in Manhattan's Financial District at 22 Cortlandt Street, with the support of experiences company LEGENDS.

Key Points: 
  • Tomorrow - May 16, 2023 -  The beloved retailer and purveyor of off-price luxury fashion is re-opening the doors of its flagship location in Manhattan's Financial District at 22 Cortlandt Street, with the support of experiences company LEGENDS.
  • New Yorkers and tourists in-the-know can now re-discover the thrill of "the hunt" as they shop luxury fashion at Century 21's head-turning prices.
  • The re-opened Cortlandt Street location houses the four main floors of the original space, with an intentional focus on Century 21's core business - fashion.
  • In celebration, Century 21 tapped NYC-based artist Timothy Goodman to create three  larger than life murals using objects and words that accentuate Century 21's place in NYC''s fashion scene.

MINERVA FOODS REPORTS CONSOLIDATED GROSS REVENUE OF R$ 6,8 BILLION IN THE FIRST QUARTER OF 2023

Retrieved on: 
Tuesday, May 9, 2023
Net, Shareholder, ALC, Minerva, LTM, Acquisition, Growth, SAO, Clothing, Bookkeeping, EBITDA

SAO PAULO, May 9, 2023 /PRNewswire/ -- Minerva Foods (Minerva S.A. – B3: BEEF3 | OTC – Nasdaq International: MRVSY), a leader in the export of fresh beef and its derivatives in South America, and which also operates in the processed segment, informs its financial results for the first quarter of 2023 (1Q23) to the market.

Key Points: 
  • Consolidated gross revenue in 1Q23 was R$ 6,8 billion, and R$ 32,1 billion in the twelve months to March 31, up by 7% on LTM1Q22 (LTM: Last twelve Months).
  • In the last twelve months ended March 31, EBITDA was R$ 2,7 billion, with an EBITDA margin of 9%.
  • In 1Q23, net revenue was R$ 114 million, stable on the last quarter of 2022.
  • The company's net revenue totaled R$ 6,4 billion in 1Q23, and in the last twelve months ended March 2023 totaled R$ 30,1 billion, up by 6,1% on LTM1Q22.

MINERVA FOODS REPORTS CONSOLIDATED GROSS REVENUE OF R$ 6,8 BILLION IN THE FIRST QUARTER OF 2023

Retrieved on: 
Tuesday, May 9, 2023
Net, Shareholder, ALC, Minerva, LTM, Acquisition, Growth, SAO, Clothing, Bookkeeping, EBITDA

SAO PAULO, May 9, 2023 /PRNewswire/ -- Minerva Foods (Minerva S.A. – B3: BEEF3 | OTC – Nasdaq International: MRVSY), a leader in the export of fresh beef and its derivatives in South America, and which also operates in the processed segment, informs its financial results for the first quarter of 2023 (1Q23) to the market.

Key Points: 
  • Consolidated gross revenue in 1Q23 was R$ 6,8 billion, and R$ 32,1 billion in the twelve months to March 31, up by 7% on LTM1Q22 (LTM: Last twelve Months).
  • In the last twelve months ended March 31, EBITDA was R$ 2,7 billion, with an EBITDA margin of 9%.
  • In 1Q23, net revenue was R$ 114 million, stable on the last quarter of 2022.
  • The company's net revenue totaled R$ 6,4 billion in 1Q23, and in the last twelve months ended March 2023 totaled R$ 30,1 billion, up by 6,1% on LTM1Q22.

EY Announces John Shen of American Lending Center as an Entrepreneur Of The Year® 2023 Pacific Southwest Award Finalist

Retrieved on: 
Monday, May 8, 2023
Finance, Business, Banking, Professional Services, Small Business, Ernst & Young Entrepreneur of the Year Award, Small business, Swamp, Pacific Southwest, ALC, EY, Ewing Marion Kauffman Foundation, Ernst & Young, PNC Financial Services, Parallel, Economic development, The Big Picture, SAP, Cresa, Growth, City, Piper, DLA Piper, Pharmaceutical industry

Ernst & Young LLP (EY US) today announced that John Shen, CEO of American Lending Center (under American Lending Center Holdings), was named an Entrepreneur Of The Year® 2023 Pacific Southwest Award finalist.

Key Points: 
  • Ernst & Young LLP (EY US) today announced that John Shen, CEO of American Lending Center (under American Lending Center Holdings), was named an Entrepreneur Of The Year® 2023 Pacific Southwest Award finalist.
  • Entrepreneurs were evaluated based on their demonstration of building long-term value through entrepreneurial spirit, purpose, growth and impact, among other core contributions and attributes.
  • “I am honored and humbled to be recognized by Ernst & Young as an Entrepreneur Of The Year® 2023 Pacific Southwest Award finalist," said John, founder of American Lending Center, private capital firm Sunstone Management , and ghost kitchen operator Partake Collective .
  • The Entrepreneur Of The Year National Overall Award winner will then move on to compete for the World Entrepreneur Of The Year® Award in June 2024.

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 8, 2023
Call, Total, AACR, TCL, PRS, ALC, RCC, Neoplasm, KCRC, ITK, Clinical trial, Extranodal NK/T-cell lymphoma, nasal type, American Association for Cancer Research, Head, T-cell lymphoma, NSCLC, Lung cancer, Immunotherapy, Bone marrow, Hematological Cancer Research Investment and Education Act, Patient, Ipilimumab, BID, Blood, Immune system, Kidney cancer, CR, Growth, Research, FDA, B16, Pembrolizumab, PR, Safety, Nivolumab, Pharmaceutical industry, Cryptocurrency, Corvus, Conference

BURLINGAME, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2023.
  • The clinical trial is expected to enroll up to 60 patients and initial data is anticipated before the end of 2023.
  • As of March 31, 2023, Corvus had cash, cash equivalents and marketable securities totaling $34.5 million.
  • The decrease of $0.5 million was primarily due to lower clinical trial and manufacturing costs associated with the development of mupadolimab.

MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy

Retrieved on: 
Tuesday, May 2, 2023
Biotechnology, General Health, Mental Health, Health, Pharmaceutical, FOR, PFE, DRS, Patent Cooperation Treaty, Annual general meeting, Acquisition, Patient, Patent, Investment, Risk, Financial management, NYSE, FCM, GAD, GW Pharmaceuticals, Research, DSM-IV codes, Aerie Pharmaceuticals, FDA, Mental health, Social media, NOT, ALC, ALL, Annual Meetings of the International Monetary Fund and the World Bank Group, Multimedia, LSD, Trustee, NEO, MindMed, Drug development, SG, Spectrum, Clinical trial, Pfizer, Celgene, RBC Capital Markets, Invention, Jazz Pharmaceuticals, EF Hutton, Psychiatry, Management, Auction, Security (finance), Pharmaceutical industry, Medical device, Alcon, ADHD

The Company has launched www.ProtectMindMed.com to keep shareholders up to date on key developments leading up to the Annual Meeting.

Key Points: 
  • The Company has launched www.ProtectMindMed.com to keep shareholders up to date on key developments leading up to the Annual Meeting.
  • The full text of the Board’s letter to shareholders, which can be viewed and downloaded here , follows:
    Thank you for your investment in MindMed.
  • Your vote at the Company’s 2023 Annual General Meeting of Shareholders, scheduled for June 15, 2023, is critically important this year.
  • Shareholders will receive proxy materials directly via the preferred method, hard copy or email, specific to each shareholder’s account.

Air Lease Corporation Extends $7.2 Billion Senior Unsecured Revolving Credit Facility

Retrieved on: 
Tuesday, April 25, 2023
Professional Services, Air, Transport, Aerospace, Manufacturing, Banking, ALC, SOFR, JPMorgan Chase, AL, Air Lease Corporation, Security (finance), Chase Bank, NYSE, Airline

Air Lease Corporation (NYSE: AL) amended and extended its senior unsecured revolving credit facility with JPMorgan Chase Bank, N.A., as administrative agent whereby the company extended the final maturity date of the facility from May 5, 2026 to May 5, 2027 and amended the total revolving commitments to approximately $7.2 billion across 49 financial institutions as of May 5, 2023.

Key Points: 
  • Air Lease Corporation (NYSE: AL) amended and extended its senior unsecured revolving credit facility with JPMorgan Chase Bank, N.A., as administrative agent whereby the company extended the final maturity date of the facility from May 5, 2026 to May 5, 2027 and amended the total revolving commitments to approximately $7.2 billion across 49 financial institutions as of May 5, 2023.
  • The senior unsecured revolving credit facility accrues interest at adjusted term SOFR plus a margin of 1.05% per year with a 0.20% facility fee, each subject to adjustments based on the company’s credit ratings.
  • “We are pleased to announce the extension of our senior unsecured revolving credit facility by one year to 2027, and we’d like to thank our bank partners for their continued support,” said Gregory B. Willis, Executive Vice President and Chief Financial Officer of Air Lease Corporation.
  • About Air Lease Corporation (NYSE: AL)
    Air Lease Corporation is a leading global aircraft leasing company based in Los Angeles, California that has airline customers throughout the world.

Licensing Show brings together over 320 exhibitors

Retrieved on: 
Saturday, April 22, 2023
Mainland China, Intellectual property, Sport, International, Senior, ALC, JP, Marketing, Van Gogh Museum, Medialink, IP, Government, Creativity, Ministry, IPS, Republic, Converse, IMG, Growth, Tourism, Rivers State Ministry of Culture and Tourism, FILA, Conference, Entertainment, Film industry, Creative industries, HKTDC, Culture

Dr Patrick Lau, Deputy Executive Director, HKTDC (centre) and Mr Lau Chun, Raistlin, JP, Under

Key Points: 
  • Dr Patrick Lau, Deputy Executive Director, HKTDC (centre) and Mr Lau Chun, Raistlin, JP, Under
    projects, featuring top global licensors and licensing agents.
  • We are pleased to see that Hong Kong continues to play a key role in linking the mainland and abroad in the licensing field, demonstrating the substantial potential of the global licensing industry."
  • Ever-changing consumer demands today made brand awareness crucial to a company's success and licensing enhanced a company's competitiveness, increased brand value and attracted consumers, he added.
  • Ms Chiu Siu Yin Lovinia, Chairman of Medialink Group, was one of the exhibitors focusing on IP and brand licensing management services.

Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 17, 2023
Antigen, T helper cell, AACR, Interferon gamma, TCL, Perforin-1, TNF, ALC, Neoplasm, Infection, ITK, Clinical trial, American Association for Cancer Research, NK, IL10, T-cell lymphoma, Cell, Publication, Immunotherapy, Colon, IL4, Hematological Cancer Research Investment and Education Act, Downregulation and upregulation, CD8, Animal, Patient, Enrollment, Melanoma, Immune system, Annual general meeting, IL17, Growth, Poster, CD4, IL9, Lymphocyte, Cytokine, FDA, ACL, B16, IL5, Tumor microenvironment, Safety, Vaccine, Pharmaceutical industry, Corvus

BURLINGAME, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced new data for CPI-818, the Company’s ITK inhibitor, demonstrating its potential to treat a variety of solid and hematological cancers based on a novel immunotherapy mechanism of action. The data will be presented today in a poster at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place April 14-19, 2023 in Orlando, FL.

Key Points: 
  • The data will be presented today in a poster at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place April 14-19, 2023 in Orlando, FL.
  • “CPI-818 inhibited tumor growth in five different tumor models including colon, renal and melanoma cancers, and in both T and B cell lymphomas.
  • These properties are a result of the myriad of functions that ITK plays in T cell biology.
  • The triplet combination led to complete tumor elimination in 19 of 20 animals with established CT26 colon cancer tumors.

REPEAT: MEDIA ADVISORY: Charter challenge by patient advocates filed against Ford government’s law overriding elderly patients’ right to consent & coercing them out of hospital

Retrieved on: 
Thursday, April 13, 2023
Ontario Superior Court of Justice, Justice, ALC, Policy and Legal Advocacy Centre, Ontario Health Coalition, Coalition, Ford, Privacy, Hospital, Patient, Physician, Application, ACE, Health, Bed, Zoom, Program of All-Inclusive Care for the Elderly, Legislation, Nursing

TORONTO, April 13, 2023 (GLOBE NEWSWIRE) -- The Ontario Health Coalition and the Advocacy Centre for the Elderly (ACE) have made a major step forward in their Charter Challenge to Bill 7, passed by the Ford government last fall. The patient advocates filed a Notice of Application with the Ontario Superior Court of Justice on Wednesday. The Application is supported by evidence from four expert physicians and a national expert in health services. The Coalition and ACE have been gathering evidence from patients and their substitute decision-makers which will also support the Application.

Key Points: 
  • The patient advocates filed a Notice of Application with the Ontario Superior Court of Justice on Wednesday.
  • The Application is supported by evidence from four expert physicians and a national expert in health services.
  • The Coalition and ACE have been gathering evidence from patients and their substitute decision-makers which will also support the Application.
  • Bill 7, More Beds, Better Care Act, despite the title neither creates more hospital or long-term care beds, nor does it improve levels of care.